Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics Q3 net loss $68.4 million, down from $15.9 million profit

Negative Impact 4 of 5 earnings

Tango Therapeutics reported a third quarter 2026 net loss of $68.4 million, or $0.39 per share, compared with net income of $15.9 million, or $0.13 per diluted share, in the same quarter of 2025. Collaboration revenue fell to $0 from $53.8 million after the Gilead collaboration concluded research activities in August 2025, while research and development and general and administrative spending both rose.

Key points

  • Collaboration revenue was $0 in Q3 2026, versus $53.8 million in Q3 2025.
  • R&D expenses rose to $48.9 million from $30.8 million; G&A expenses rose to $29.2 million from $8.9 million.
  • Cash, cash equivalents and marketable securities totaled $977.5 million as of September 30, 2026.
  • Tango intends to initiate a Phase 3 study of vopimetostat plus daraxonrasib in front-line pancreatic cancer in the first half of 2027.

The filing

CompanyTango Therapeutics, Inc. (TNGX)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:13 AM ET
Accession number0001193125-26-452635

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:18 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.